{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:37Z","timestamp":1787026657668,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2018.00238","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T01:10:41Z","timestamp":1536023441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature"],"prefix":"10.3389","volume":"5","author":[{"given":"Rikke","family":"Bech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Kibsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2340\/00015555-1925","article-title":"A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre","volume":"95","author":"Kibsgaard","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/exd.13401","article-title":"Neurological and psychiatric associations in bullous pemphigoid\u2014more than skin deep?","volume":"26","author":"F\u00f6rsti","year":"2017","journal-title":"Exp Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaad.2014.05.006","article-title":"Mortality of patients with bullous pemphigoid in Korea","volume":"71","author":"Lee","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijd.12619","article-title":"Survey of bullous pemphigoid disease in northern iran","volume":"54","author":"Banihashemi","year":"2015","journal-title":"Int J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2249.2012.04674.x","article-title":"Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease","volume":"171","author":"Marzano","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.yexcr.2009.11.010","article-title":"BPAG1 Isoform-b: complex distribution pattern in striated and heart muscle and association with plectin and \u03b1-actinin","volume":"316","author":"Steiner-Champliaud","year":"2010","journal-title":"Expe Cell Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1101\/gad.11.23.3143","article-title":"Targeted inactivation of plectin reveals essential function in maintaining the integrity of skin, muscle, and heart cytoarchitecture","volume":"11","author":"Andr\u00e4","year":"1997","journal-title":"Genes Dev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e9465","DOI":"10.1371\/journal.pone.0009465","article-title":"Hearts of Dystonia musculorum mice display normal morphological and histological features but show signs of cardiac stress","volume":"5","author":"Boyer","year":"2010","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E368","DOI":"10.3390\/ijms19020368","article-title":"Microtubule-actin crosslinking factor 1 and plakins as therapeutic drug targets","volume":"19","author":"Quick","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U","volume":"176","author":"Ren","year":"2017","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"37125","DOI":"10.1038\/srep37125","article-title":"Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide finnish care register study","volume":"6","author":"F\u00f6rsti","year":"2016","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1590\/abd1806-4841.20142516","article-title":"Bullous pemphigoid and comorbidities: a case-control study in portuguese patients","volume":"89","author":"Teixeira","year":"2014","journal-title":"Anais Bras Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6053267","DOI":"10.1155\/2017\/6053267","article-title":"Frequency of neurological disorders in bullous pemphigoid patients: a cross-sectional study","volume":"2017","author":"Khosravani","year":"2017","journal-title":"Int Sch Res Notices"},{"key":"B16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1590\/abd1806-4841.20153334","article-title":"Bullous pemphigoid and neurological disease: statistics from a dermatology service","volume":"90","author":"Tarazona","year":"2015","journal-title":"Anais Bras Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jaad.2014.07.052","article-title":"A population-based study of the association between bullous pemphigoid and neurologic disorders","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.adengl.2014.09.010","article-title":"Association between bullous pemphigoid and neurologic diseases: a case-control study","volume":"105","author":"Casas-de-la-Asunci\u00f3n","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/ceji.2017.67322","article-title":"Analysis of the autoimmune response against BP180 and BP230 in ethnic poles with neurodegenerative disorders and bullous pemphigoid","volume":"42","author":"Gornowicz-Porowska","year":"2017","journal-title":"Central Eur J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semcdb.2017.06.005","article-title":"BPAG1, a distinctive role in skin and neurological diseases","volume":"69","author":"Ali","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/jdv.12995","article-title":"Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations","volume":"29","author":"Gambichler","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/jdv.12136","article-title":"Immunopathological characteristics of patients with bullous pemphigoid and neurological disease","volume":"28","author":"Taghipour","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2340\/00015555-2347","article-title":"Risk of death in bullous pemphigoid: a retrospective database study in finland","volume":"17","author":"F\u00f6rsti","year":"2014","journal-title":"Acta Dermato Venereol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","article-title":"Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in poland","volume":"309","author":"Kalinska-Bienias","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"700.e3","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000469710","article-title":"Increased risk of bullous pemphigoid after first-ever stroke: a population-based study","volume":"17","author":"Shen","year":"2017","journal-title":"Neurodegener Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/jdv.12155","article-title":"Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients","volume":"28","author":"Gual","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/1744-9987.12536","article-title":"Bullous pemphigoid successfully treated with a combination therapy of plasmapheresis followed by intravenous high dose immunoglobulin","volume":"21","author":"Kaneda","year":"2017","journal-title":"Ther Apheresis Dial"},{"key":"B35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2450\/2014.0222-13","article-title":"Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature","volume":"12","author":"Chang","year":"2014","journal-title":"Blood Transfus"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13970","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21100","article-title":"A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 Mg\/Day) with that of oral prednisolone (0","volume":"21","author":"Chalmers","year":"2017","journal-title":"Health Technol Assess"},{"key":"B38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.det.2011.06.018","article-title":"Dapsone in the management of autoimmune bullous diseases","volume":"29","author":"Piette","year":"2012","journal-title":"Immunol Allergy Clin North Am"},{"key":"B39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"Grcan","year":"2009","journal-title":"Am J Clin Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T01:10:43Z","timestamp":1536023443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2018.00238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":39,"alternative-id":["10.3389\/fmed.2018.00238"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2018.00238","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"article-number":"238"}}